U.S. Stock Market Midday Update

Sangrix fell 17.62%. Based on recent news,

1. On September 8, Sagimet Biosciences advanced its late-stage acne trial, leading to reduced market attention on Sangrix. The progress made by Sagimet Biosciences in its late-stage acne trial attracted investor attention, causing Sangrix's stock price to decline.

2. On September 8, Capricor Therapeutics faced regulatory hurdles from the FDA, affecting investment sentiment across the biotechnology sector. Capricor Therapeutics encountered regulatory resistance due to a negative vote from the FDA advisory panel regarding the efficacy of its drug and an extension of the PDUFA date, leading to a downturn in investment sentiment in the biotechnology sector, which impacted Sangrix's stock price.

3. On September 8, the market expressed concerns over the policy spillover effects of the upcoming central bank meeting, leading to a repricing of peripheral assets. As the next key central bank meeting approaches, concerns about policy spillover effects have intensified, causing a repricing of peripheral assets, which affected Sangrix's stock price. The market is worried about the spillover effects of central bank policies.

Top Stocks by Trading Volume in the Industry

S&P Global fell 4.26%. Based on recent key news:

1. On September 4, S&P Global director Craig Conway sold 4,500 shares of common stock at an average price of $260.5 per share. This sale may raise market concerns about internal confidence in the company, leading to a decline in stock price.

2. On September 8, S&P Global announced a quarterly dividend of R$0.07 per unit. Although this is a positive financial move, it failed to boost the stock price, reflecting market concerns about the company's future profitability.

3. On September 8, market analysts noted that S&P Global's latest financial report did not change its position on analysts' recommendation lists. Despite a rating of moderate buy, it failed to attract the attention of top analysts, affecting market confidence. The rapid development of AI technology has led to significant industry differentiation.

Palantir Tech fell 1.06%, with increased trading volume. Based on recent key news:

1. On September 8, Cathie Wood's Ark Invest sold $25 million worth of Palantir stock. This move drew market attention, as Wood has been a supporter of Palantir, putting pressure on the stock price.

2. On September 8, Palantir announced a strategic partnership with Nebius to promote the development of sovereign AI infrastructure. Despite the positive outlook of the partnership, it failed to boost the stock price in the short term.

3. On September 7, Palantir secured a production contract for the U.S. Army's TITAN AI system, resulting in a 149% increase in commercial revenue. However, concerns about its valuation remain, limiting the stock price's rise AI drives growth in the SaaS industry, market sentiment is complex.

Strategy fell 3.03%, with active trading. Based on recent key news:

1. On September 8, Strategy announced the expansion of its digital credit securities repurchase program from $1 billion to $2 billion. This raised concerns in the market about the company's cash flow, causing the stock price to drop by 3.41%. Source: Titanium Media App

2. On September 5, Bitcoin prices rebounded by about 23% at the end of August, prompting companies to increase their allocation to crypto assets. During this period, Strategy increased its holdings by 4,603 Bitcoins, with total holdings exceeding 845,000 BTC. Source: Jinse Finance

3. On September 8, Strategy disclosed that its US dollar cash reserves had fallen to $6.538 billion, raising doubts in the market about its financial health, which affected stock performance. Source: Odaily Bitcoin price fluctuations impact crypto stock performance, market is concerned.

Stocks ranked at the top of the industry by market capitalization

SAP fell 2.17%, with increased trading volume. Based on recent key news:

1. On September 7, the European Commission accepted SAP's commitments, ending the investigation into competition restrictions in its ERP software aftermarket. This move provides customers with more choices, especially in terms of third-party support, which may lead to market concerns about SAP's future revenue, affecting the stock price decline.

2. On September 7, a Gartner report indicated that SAP's per-employee subscription model is two to five times more expensive than traditional versions, raising market doubts about its pricing strategy, which may impact investor confidence and lead to a decline in stock price. The tech industry faces challenges in pricing strategies